# A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

> **NCT00405054** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 52 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** MK0457

## Key facts

- **NCT ID:** NCT00405054
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405054, "A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00405054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*